Therapeutics targeting the inflammasome after central nervous system injury

Translational Research

Volumn 167, Issue 1, 2016, Pages 35-45

  De Rivero Vaccari, Juan Pablo ^a   Dietrich, W Dalton ^a   Keane, Robert W ^a,b  

^a Lois Pope LIFE Center ^*  (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATASE; ALTEPLASE; BELNACASAN; BETA SECRETASE 1; CEREBROLYSIN; CORTICOSTEROID; CYCLOSPORIN A; ERYTHROPOIETIN; FIBROBLAST GROWTH FACTOR; GACYCLIDINE; GANGLIOSIDE GM1; GINSENOSIDE RD; HEAT SHOCK PROTEIN 90; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INFLAMMASOME; INHIBITOR OF APOPTOSIS PROTEIN; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME; MAGNESIUM; METHYLPREDNISOLONE; MINOCYCLINE; NEUROTROPHIC FACTOR; NIMODIPINE; PRALNACASAN; PROGESTERONE; PROTIRELIN; PURINERGIC P2X4 RECEPTOR; REACTIVE OXYGEN METABOLITE; SMALL INTERFERING RNA;

BRAIN DAMAGE; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; DRUG EFFICACY; DRUG SAFETY; ENZYME ACTIVATION; EPILEPSY; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; FOCAL EPILEPSY; HEART INFARCTION; HUMAN; INNATE IMMUNITY; MOTOR PERFORMANCE; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; REVIEW; RHEUMATOID ARTHRITIS; SPINAL CORD INJURY; SUBARACHNOID HEMORRHAGE; TRANSIENT ISCHEMIC ATTACK; TRAUMATIC BRAIN INJURY; ANIMAL; IMMUNOLOGY; INFLAMMATION; TRAUMA, NERVOUS SYSTEM;

ANIMALS; HUMANS; IMMUNITY, INNATE; INFLAMMASOMES; INFLAMMATION; TRAUMA, NERVOUS SYSTEM;

EID: 84952639919     PISSN: 19315244     EISSN: 18781810     Source Type: Journal    
DOI: 10.1016/j.trsl.2015.05.003     Document Type: Review

References (112)

1. F. Martinon, K. Burns, and J. Tschopp The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta Mol Cell 10 2002 417 426
2. O. Piazza, G. Scarpati, S. Cotena, M. Lonardo, and R. Tufano Thrombin antithrombin complex and IL-18 serum levels in stroke patients Neurol Int 2 2010 e1
3. B.J. Jefferis, P.H. Whincup, P. Welsh, and et al. Prospective study of IL-18 and risk of MI and stroke in men and women aged 60-79 years: a nested case-control study Cytokine 61 2013 513 520
4. J.T. Cvetkovic, P.G. Wiklund, E. Ahmed, L. Weinehall, G. Hallmans, and A.K. Lefvert Polymorphisms of IL-1beta, IL-1Ra, and TNF-alpha genes: a nested case-control study of their association with risk for stroke J Stroke Cerebrovasc Dis 14 2005 29 35
5. P.J. Hutchinson, M.T. O'Connell, N.J. Rothwell, and et al. Inflammation in human brain injury: intracerebral concentrations of IL-1alpha, IL-1beta, and their endogenous inhibitor IL-1ra J Neurotrauma 24 2007 1545 1557
6. A. Ciaramella, C. Della Vedova, F. Salani, and et al. Increased levels of serum IL-18 are associated with the long-term outcome of severe traumatic brain injury Neuroimmunomodulation 21 2014 8 12
7. N. Kostulas, S.H. Pelidou, P. Kivisakk, V. Kostulas, and H. Link Increased IL-1beta, IL-8, and IL-17 mRNA expression in blood mononuclear cells observed in a prospective ischemic stroke study Stroke 30 1999 2174 2179
8. I. Yatsiv, M.C. Morganti-Kossmann, D. Perez, and et al. Elevated intracranial IL-18 in humans and mice after traumatic brain injury and evidence of neuroprotective effects of IL-18-binding protein after experimental closed head injury J Cereb Blood Flow Metab 22 2002 971 978
9. P. Bossu, F. Salani, C. Cacciari, and et al. Disease outcome, alexithymia and depression are differently associated with serum IL-18 levels in acute stroke Curr Neurovasc Res 6 2009 163 170
10. E. Vigano, and A. Mortellaro Caspase-11: the driving factor for noncanonical inflammasomes Eur J Immunol 43 2013 2240 2245
11. S.E. Adamczak, J.P. de Rivero Vaccari, G. Dale, and et al. Pyroptotic neuronal cell death mediated by the AIM2 inflammasome J Cereb Blood Flow Metab 34 2014 621 629
12. J.P. de Rivero Vaccari, G. Lotocki, O.F. Alonso, H.M. Bramlett, W.D. Dietrich, and R.W. Keane Therapeutic neutralization of the NLRP1 inflammasome reduces the innate immune response and improves histopathology after traumatic brain injury J Cereb Blood Flow Metab 29 2009 1251 1261
13. J.P. de Rivero Vaccari, G. Lotocki, A.E. Marcillo, W.D. Dietrich, and R.W. Keane A molecular platform in neurons regulates inflammation after spinal cord injury J Neurosci 28 2008 3404 3414
14. J. Minkiewicz, J.P. de Rivero Vaccari, and R.W. Keane Human astrocytes express a novel NLRP2 inflammasome Glia 61 2013 1113 1121
15. S.T. Beug, H.H. Cheung, E.C. LaCasse, and R.G. Korneluk Modulation of immune signalling by inhibitors of apoptosis Trends Immunol 33 2012 535 545
16. D.P. Abulafia, J.P. de Rivero Vaccari, J.D. Lozano, G. Lotocki, R.W. Keane, and W.D. Dietrich Inhibition of the inflammasome complex reduces the inflammatory response after thromboembolic stroke in mice J Cereb Blood Flow Metab 29 2009 534 544
17. F. Madouri, N. Guillou, L. Fauconnier, and et al. Caspase-1 activation by NLRP3 inflammasome dampens IL-33-dependent house dust mite-induced allergic lung inflammation J Mol Cell Biol 2015 [Epub ahead of print]
18. S.P. Gadani, J.T. Walsh, I. Smirnov, J. Zheng, and J. Kipnis The glia-derived alarmin IL-33 orchestrates the immune response and promotes recovery following CNS injury Neuron 85 2015 703 709
19. M.E. Bianchi DAMPs, PAMPs and alarmins: all we need to know about danger J Leukoc Biol 81 2007 1 5
20. D. Tang, R. Kang, C.B. Coyne, H.J. Zeh, and M.T. Lotze PAMPs and DAMPs: signal 0s that spur autophagy and immunity Immunol Rev 249 2012 158 175
21. J.C. de Rivero Vaccari, F.J. Brand 3rd, A.F. Berti, O.F. Alonso, M.R. Bullock, and J.P. de Rivero Vaccari Mincle signaling in the innate immune response after traumatic brain injury J Neurotrauma 32 2015 228 236
22. K.A. Kigerl, J.P. de Rivero Vaccari, W.D. Dietrich, P.G. Popovich, and R.W. Keane Pattern recognition receptors and central nervous system repair Exp Neurol 258 2014 5 16
23. E. Latz, T.S. Xiao, and A. Stutz Activation and regulation of the inflammasomes Nat Rev Immunol 13 2013 397 411
24. T. Lane, B. Flam, R. Lockey, and N. Kolliputi TXNIP shuttling: missing link between oxidative stress and inflammasome activation Front Physiol 4 2013 50
25. W.R. Silverman, J.P. de Rivero Vaccari, S. Locovei, and et al. The pannexin 1 channel activates the inflammasome in neurons and astrocytes J Biol Chem 284 2009 18143 18151
26. J.P. de Rivero Vaccari, D. Bastien, G. Yurcisin, and et al. P2X4 receptors influence inflammasome activation after spinal cord injury J Neurosci 32 2012 3058 3066
27. A.K. Varma, A. Das, W. Gt, and et al. Spinal cord injury: a review of current therapy, future treatments, and basic science frontiers Neurochem Res 38 2013 895 905
28. A. Ackery, C. Tator, and A. Krassioukov A global perspective on spinal cord injury epidemiology J Neurotrauma 21 2004 1355 1370
29. C.H. Tator Review of treatment trials in human spinal cord injury: issues, difficulties, and recommendations Neurosurgery 59 2006 957 982
30. W.P. Coleman, D. Benzel, D.W. Cahill, and et al. A critical appraisal of the reporting of the National Acute Spinal Cord Injury Studies (II and III) of methylprednisolone in acute spinal cord injury J Spinal Disord 13 2000 185 199
31. R.J. Dumont, S. Verma, D.O. Okonkwo, and et al. Acute spinal cord injury, part II: contemporary pharmacotherapy Clin Neuropharmacol 24 2001 265 279
32. E.M. Kan, E.A. Ling, and J. Lu Stem cell therapy for spinal cord injury Curr Med Chem 17 2010 4492 4510
33. V. Pointillart, M.E. Petitjean, L. Wiart, and et al. Pharmacological therapy of spinal cord injury during the acute phase Spinal Cord 38 2000 71 76
34. M.G. Fehlings, and D.C. Baptiste Current status of clinical trials for acute spinal cord injury Injury 36 suppl 2 2005 B113 B122
35. A.I. Faden Opiate-receptor antagonists, thyrotropin-releasing hormone (TRH), and TRH analogs in the treatment of spinal cord injury Cent Nerv Syst Trauma 4 1987 217 226
36. P. Chinnock, and I. Roberts Gangliosides for acute spinal cord injury Cochrane Database Syst Rev 2 2005 CD004444
37. M.G. Fehlings, N. Theodore, J. Harrop, and et al. A phase I/IIa clinical trial of a recombinant Rho protein antagonist in acute spinal cord injury J Neurotrauma 28 2011 787 796
38. E. Ibrahim, S.M. Castle, T.C. Aballa, and et al. Neutralization of ASC improves sperm motility in men with spinal cord injury Hum Reprod 29 2014 2368 2373
39. X. Zhang, E. Ibrahim, J.P. de Rivero Vaccari, and et al. Involvement of the inflammasome in abnormal semen quality of men with spinal cord injury Fertil Steril 99 2013 118 124
40. A.I. Maas, N. Stocchetti, and R. Bullock Moderate and severe traumatic brain injury in adults Lancet Neurol 7 2008 728 741
41. C.W. Hoge, D. McGurk, J.L. Thomas, A.L. Cox, C.C. Engel, and C.A. Castro Mild traumatic brain injury in U.S. soldiers returning from Iraq N Engl J Med 358 2008 453 463
42. H.M. Bramlett, and W.D. Dietrich Progressive damage after brain and spinal cord injury: pathomechanisms and treatment strategies Prog Brain Res 161 2007 125 141
43. S.V. Kabadi, and A.I. Faden Neuroprotective strategies for traumatic brain injury: improving clinical translation Int J Mol Sci 15 2014 1216 1236
44. T.K. McIntosh, D.H. Smith, and E. Garde Therapeutic approaches for the prevention of secondary brain injury Eur J Anaesthesiol 13 1996 291 309
45. A.I. Faden Neuroprotection and traumatic brain injury: theoretical option or realistic proposition Curr Opin Neurol 15 2002 707 712
46. D.G. Stein Progesterone in the treatment of acute traumatic brain injury: a clinical perspective and update Neuroscience 191 2011 101 106
47. D.W. Wright, A.L. Kellermann, V.S. Hertzberg, and et al. ProTECT: a randomized clinical trial of progesterone for acute traumatic brain injury Ann Emerg Med 49 2007 391 402.e1-e2
48. L.L. Ponce, J.C. Navarro, O. Ahmed, and C.S. Robertson Erythropoietin neuroprotection with traumatic brain injury Pathophysiology 20 2013 31 38
49. R. Nirula, R. Diaz-Arrastia, K. Brasel, J.A. Weigelt, and K. Waxman Safety and efficacy of erythropoietin in traumatic brain injury patients: a pilot randomized trial Crit Care Res Pract 2010 1 5
50. D.W. Marion Decompressive craniectomy in diffuse traumatic brain injury Lancet Neurol 10 2011 497 498
51. W.D. Dietrich, and H.M. Bramlett The evidence for hypothermia as a neuroprotectant in traumatic brain injury Neurotherapeutics 7 2010 43 50
52. S. Yokobori, K. Hosein, S. Burks, I. Sharma, S. Gajavelli, and R. Bullock Biomarkers for the clinical differential diagnosis in traumatic brain injury - a systematic review CNS Neurosci Ther 19 2013 556 565
53. E.F. Wible, and D.T. Laskowitz Statins in traumatic brain injury Neurotherapeutics 7 2010 62 73
54. A.T. Mazzeo, O.L. Alves, C.B. Gilman, and et al. Brain metabolic and hemodynamic effects of cyclosporin A after human severe traumatic brain injury: a microdialysis study Acta Neurochir 150 2008 1019 1031 discussion 31
55. H.D. Liu, W. Li, Z.R. Chen, and et al. Expression of the NLRP3 inflammasome in cerebral cortex after traumatic brain injury in a rat model Neurochem Res 38 2013 2072 2083
56. S. Adamczak, G. Dale, J.P. de Rivero Vaccari, M.R. Bullock, W.D. Dietrich, and R.W. Keane Inflammasome proteins in cerebrospinal fluid of brain-injured patients as biomarkers of functional outcome: clinical article J Neurosurg 117 2012 1119 1125
57. S. Tomura, J.P. de Rivero Vaccari, R.W. Keane, H.M. Bramlett, and W.D. Dietrich Effects of therapeutic hypothermia on inflammasome signaling after traumatic brain injury J Cereb Blood Flow Metab 32 2012 1939 1947
58. A. Majid Neuroprotection in stroke: past, present, and future ISRN Neurol 2014 2014 515716
59. M. Tymianski Novel approaches to neuroprotection trials in acute ischemic stroke Stroke 44 2013 2942 2950
60. S.D. Reed, S.C. Cramer, D.K. Blough, K. Meyer, and J.G. Jarvik Treatment with tissue plasminogen activator and inpatient mortality rates for patients with ischemic stroke treated in community hospitals Stroke 32 2001 1832 1840
61. A.R. Noorian, R. Gupta, and R.G. Nogueira Stenting of complete vertebral artery ostial occlusion in a patient with medically refractory vertebrobasilar ischemia J Neurointerv Surg 4 2012 e31
62. V.E. O'Collins, M.R. Macleod, G.A. Donnan, L.L. Horky, B.H. van der Worp, and D.W. Howells 1,026 Experimental treatments in acute stroke Ann Neurol 59 2006 467 477
63. J.L. Saver, S. Starkman, M. Eckstein, and et al. Prehospital use of magnesium sulfate as neuroprotection in acute stroke N Engl J Med 372 2015 528 536
64. S.M. Dorhout Mees MASH-II Study Group Magnesium in aneurysmal subarachnoid hemorrhage (MASH II) phase III clinical trial MASH-II study group Int J Stroke 3 2008 63 65
65. A. Davalos, J. Alvarez-Sabin, J. Castillo, and et al. Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial) Lancet 380 2012 349 357
66. W.D. Heiss, M. Brainin, N.M. Bornstein, J. Tuomilehto, and Z. Hong Cerebrolysin acute stroke treatment in Asia I. Cerebrolysin in patients with acute ischemic stroke in Asia: results of a double-blind, placebo-controlled randomized trial Stroke 43 2012 630 636
67. X. Liu, L. Wang, A. Wen, and et al. Ginsenoside-Rd improves outcome of acute ischaemic stroke - a randomized, double-blind, placebo-controlled, multicenter trial Eur J Neurol 19 2012 855 863
68. I.N. Mohamed, T. Ishrat, S.C. Fagan, and A.B. El-Remessy Role of inflammasome activation in the pathophysiology of vascular diseases of the neurovascular unit Antioxid Redox Signal 22 2014 1188 1206
69. D.Y. Fann, S.Y. Lee, S. Manzanero, and et al. Intravenous immunoglobulin suppresses NLRP1 and NLRP3 inflammasome-mediated neuronal death in ischemic stroke Cell Death Dis 4 2013 e790
70. Q. Ma, S. Chen, Q. Hu, H. Feng, J.H. Zhang, and J. Tang NLRP3 inflammasome contributes to inflammation after intracerebral hemorrhage Ann Neurol 75 2014 209 219
71. A. Mayor, F. Martinon, T. De Smedt, V. Petrilli, and J. Tschopp A crucial function of SGT1 and HSP90 in inflammasome activity links mammalian and plant innate immune responses Nat Immunol 8 2007 497 503
72. N.B. Bryan, A. Dorfleutner, S.J. Kramer, C. Yun, Y. Rojanasakul, and C. Stehlik Differential splicing of the apoptosis-associated speck like protein containing a caspase recruitment domain (ASC) regulates inflammasomes J Inflamm 7 2010 23
73. B.S. Franklin, L. Bossaller, D. De Nardo, and et al. The adaptor ASC has extracellular and 'prionoid' activities that propagate inflammation Nat Immunol 15 2014 727 737
74. T. Fernandes-Alnemri, J. Wu, J.W. Yu, and et al. The pyroptosome: a supramolecular assembly of ASC dimers mediating inflammatory cell death via caspase-1 activation Cell Death Differ 14 2007 1590 1604
75. S.L. Fink, T. Bergsbaken, and B.T. Cookson Anthrax lethal toxin and Salmonella elicit the common cell death pathway of caspase-1-dependent pyroptosis via distinct mechanisms Proc Natl Acad Sci U S A 105 2008 4312 4317
76. Adamczak SE. Molecular recognition of DNA by the AIM2 inflammasome induces neuronal pyroptosis: implications in infection and host tissue damage. Open Access Dissertations; 2012 (Paper 854).
77. A. Baroja-Mazo, F. Martin-Sanchez, A.I. Gomez, and et al. The NLRP3 inflammasome is released as a particulate danger signal that amplifies the inflammatory response Nat Immunol 15 2014 738 748
78. J.P. de Rivero Vaccari, F. Brand 3rd, S. Adamczak, and et al. Exosome-mediated inflammasome signaling after central nervous system injury J Neurochem 2015 [Epub ahead of print]
79. L. Alvarez-Erviti, Y. Seow, H. Yin, C. Betts, S. Lakhal, and M.J. Wood Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes Nat Biotechnol 29 2011 341 345
80. C. Fruhbeis, D. Frohlich, W.P. Kuo, and et al. Neurotransmitter-triggered transfer of exosomes mediates oligodendrocyte-neuron communication PLoS Biol 11 2013 e1001604
81. S. Pant, H. Hilton, and M.E. Burczynski The multifaceted exosome: biogenesis, role in normal and aberrant cellular function, and frontiers for pharmacological and biomarker opportunities Biochem Pharmacol 83 2012 1484 1494
82. M.L. Block, and J.S. Hong Microglia and inflammation-mediated neurodegeneration: multiple triggers with a common mechanism Prog Neurobiol 76 2005 77 98
83. U. Dirnagl, C. Iadecola, and M.A. Moskowitz Pathobiology of ischaemic stroke: an integrated view Trends Neurosci 22 1999 391 397
84. S.M. Lucas, N.J. Rothwell, and R.M. Gibson The role of inflammation in CNS injury and disease Br J Pharmacol 147 suppl 1 2006 S232 S240
85. R.C. Coll, A. Robertson, M. Butler, M. Cooper, and L.A. O'Neill The cytokine release inhibitory drug CRID3 targets ASC oligomerisation in the NLRP3 and AIM2 inflammasomes PLoS One 6 2011 e29539
86. Q.J. Shi, L. Xiao, B. Zhao, and et al. Intracerebroventricular injection of HAMI 3379, a selective cysteinyl leukotriene receptor 2 antagonist, protects against acute brain injury after focal cerebral ischemia in rats Brain Res 1484 2012 57 67
87. Q.F. Lenz, D.S. Arroyo, F.R. Temp, and et al. Cysteinyl leukotriene receptor (CysLT) antagonists decrease pentylenetetrazol-induced seizures and blood-brain barrier dysfunction Neuroscience 277 2014 859 871
88. S.B. Cohen, L.W. Moreland, J.J. Cush, and et al. A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate Ann Rheum Dis 63 2004 1062 1068
89. C.J. Smith, H.C. Emsley, C.T. Udeh, and et al. Interleukin-1 receptor antagonist reverses stroke-associated peripheral immune suppression Cytokine 58 2012 384 389
90. A.D. Greenhalgh, J. Galea, A. Denes, P.J. Tyrrell, and N.J. Rothwell Rapid brain penetration of interleukin-1 receptor antagonist in rat cerebral ischaemia: pharmacokinetics, distribution, protection Br J Pharmacol 160 2010 153 159
91. V. Banwell, E.S. Sena, and M.R. Macleod Systematic review and stratified meta-analysis of the efficacy of interleukin-1 receptor antagonist in animal models of stroke J Stroke Cerebrovasc Dis 18 2009 269 276
92. J.B. Kuemmerle-Deschner, E. Ramos, N. Blank, and et al. Canakinumab (ACZ885, a fully human IgG1 anti-IL-1beta mAb) induces sustained remission in pediatric patients with cryopyrin-associated periodic syndrome (CAPS) Arthritis Res Ther 13 2011 R34
93. A. Abbate, B.W. Van Tassell, and G.G. Biondi-Zoccai Blocking interleukin-1 as a novel therapeutic strategy for secondary prevention of cardiovascular events BioDrugs 26 2012 217 233
94. F. Clausen, A. Hanell, M. Bjork, and et al. Neutralization of interleukin-1beta modifies the inflammatory response and improves histological and cognitive outcome following traumatic brain injury in mice Eur J Neurosci 30 2009 385 396
95. F. Clausen, A. Hanell, C. Israelsson, and et al. Neutralization of interleukin-1beta reduces cerebral edema and tissue loss and improves late cognitive outcome following traumatic brain injury in mice Eur J Neurosci 34 2011 110 123
96. P.M. Ridker, T. Thuren, A. Zalewski, and P. Libby Interleukin-1beta inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS) Am Heart J 162 2011 597 605
97. P. Mistry, J. Reid, I. Pouliquen, and et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of single-dose antiinterleukin-18 mAb GSK1070806 in healthy and obese subjects Int J Clin Pharmacol Ther 52 2014 867 879
98. K. Rudolphi, N. Gerwin, N. Verzijl, P. van der Kraan, and W. van den Berg Pralnacasan, an inhibitor of interleukin-1beta converting enzyme, reduces joint damage in two murine models of osteoarthritis Osteoarthritis Cartilage 11 2003 738 746
99. B. Siegmund, and M. Zeitz Pralnacasan (vertex pharmaceuticals) IDrugs 6 2003 154 158
100. J. Ross, D. Brough, R.M. Gibson, S.A. Loddick, and N.J. Rothwell A selective, non-peptide caspase-1 inhibitor, VRT-018858, markedly reduces brain damage induced by transient ischemia in the rat Neuropharmacology 53 2007 638 642
101. F.M. Noe, N. Polascheck, F. Frigerio, and et al. Pharmacological blockade of IL-1beta/IL-1 receptor type 1 axis during epileptogenesis provides neuroprotection in two rat models of temporal lobe epilepsy Neurobiol Dis 59 2013 183 193
102. L. Dong, H. Qiao, X. Zhang, and et al. Parthenolide is neuroprotective in rat experimental stroke model: downregulating NF-kappaB, phospho-p38MAPK, and caspase-1 and ameliorating BBB permeability Mediators Inflamm 2013 2013 370804
103. M.L. Guzman, R.M. Rossi, S. Neelakantan, and et al. An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells Blood 110 2007 4427 4435
104. S. Mariathasan, D.S. Weiss, K. Newton, and et al. Cryopyrin activates the inflammasome in response to toxins and ATP Nature 440 2006 228 232
105. F.M. Ashcroft ATP-sensitive potassium channelopathies: focus on insulin secretion J Clin Invest 115 2005 2047 2058
106. M. Lamkanfi, J.L. Mueller, A.C. Vitari, and et al. Glyburide inhibits the Cryopyrin/Nalp3 inflammasome J Cell Biol 187 2009 61 70
107. N.D. Neufeld, M. Harris, L.M. Corbo, and A. Koduri Effect of glyburide in type II diabetes mellitus. Studies of monocyte membrane fluidity, lipid composition, and insulin binding Diabetes 36 1987 1351 1355
108. C. Marchetti, J. Chojnacki, S. Toldo, and et al. A novel pharmacologic inhibitor of the NLRP3 inflammasome limits myocardial injury after ischemia-reperfusion in the mouse J Cardiovasc Pharmacol 63 2014 316 322
109. R.C. Coll, A.A. Robertson, J.J. Chae, and et al. A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases Nat Med 21 2015 248 255
110. E.C. Keystone, M.M. Wang, M. Layton, S. Hollis, I.B. McInnes, and D.C.S. Team Clinical evaluation of the efficacy of the P2X7 purinergic receptor antagonist AZD9056 on the signs and symptoms of rheumatoid arthritis in patients with active disease despite treatment with methotrexate or sulphasalazine Ann Rheum Dis 71 2012 1630 1635
111. E. Ozaki, M. Campbell, and S.L. Doyle Targeting the NLRP3 inflammasome in chronic inflammatory diseases: current perspectives J Inflamm Res 8 2015 15 27
112. R.A. North, and M.F. Jarvis P2X receptors as drug targets Mol Pharmacol 83 2013 759 769